Appl. No. 10/614,959

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1-22. (Canceled)

- 1. 23 (Currently amended). An isolated antibody or antigen binding fragment thereof which:
  - (a) specifically binds a factor IX/IXa Gla domain; and
  - (b) comprises a heavy chain and a light chain variable region further wherein:
  - (i) the heavy chain variable region comprises a CDR1 which is SEQ ID NO:10, a CDR2 which is SEQ ID NO:11 and a CDR3 which is SEQ ID NO:12; and
  - (ii) the light chain variable region comprises an le a CDR1 which is SEQ ID NO:13, and le a CDR2 which is SEQ ID NO:14, and an le a CDR3 which is SEQ ID NO:15.
- 24 (Previously presented). A composition comprising the antibody or antigen binding fragment of Claim 23 and a carrier, excipient or stabilizer.
- 325 (Previously presented). The composition of Claim 24, wherein the carrier, excipient or stabilizer is pharmaceutically-acceptable.
- 4 26 (Previously presented). The composition of Claim 25, which is sterile.
- 5 21 (Previously presented). The composition of Claim 26 further comprising a thrombolytic agent.
- (Previously presented). The composition of Claim 21 wherein the thrombolytic agent is tissue plasminogen activator.
- 7 29 (Previously presented). The composition of Claim 21 wherein the thrombolytic agent is streptokinase.
- 8 36 (Previously presented). The composition of Claim 21 wherein the thrombolytic agent is urokinase.

Appl. No. 10/614,959 Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

9 (Previously presented). The composition of Claim 27 wherein the thrombolytic agent is an isolated streptokinase plasminogen.

1022 (Previously presented). The composition of Claim 26 which is lyophilized.

1 33 (Previously presented). The composition of Claim 26 which is liquid.

1234 (Previously presented). The composition of Claim 24 which is lyophilized.

13 35 (Previously presented). The composition of Claim 31 which is liquid.

1436 (Previously presented). An article of manufacture comprising;

- (a) a container;
- (b) a label on said container; and
- (c) a composition comprising an antibody or antibody fragment of Claim 23 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

1537 (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 26 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

16 28 (Previously presented). An article of manufacture comprising:

Appl. No. 10/614,959

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 27 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

(Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 28 within said container; wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

18 40 (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 29 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

1941 (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 30 within said container;

Appl. No. 10/614,959

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.

Patent Docket P1661R2

20 Az (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 31 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulapathic disorder.